Case Report: Rapamycin treatment of Osteopenia

[channel_locks]

Unexpected Increase in Bone Mineral Density With Rapamycin and Low-Dose Naltrexone: A Case Report of a 52-Year-Old Woman With Osteopenia

This case report presents a 52-year-old Caucasian female patient with osteopenia who experienced an unexpected 15.9% increase in lumbar spine BMD within two years after enrolling in a clinical trial involving low-dose rapamycin and subsequently starting low-dose naltrexone. This case potentially opens novel treatment strategies for bone density improvement in aging populations.

[Elizabeth_Kirby]

So was it the rapa or the low-dose naltrexone? And was it a n of 1 or could it apply in general?

I hope they do some experiments to sort that out. In the meantime, how would one get the LDN?

[KarlT]

@Elizabeth_Kirby

So was it the rapa or the low-dose naltrexone? And was it a n of 1 or could it apply in general?

This creates more questions than it answers. Needs further investigation.

[John_Hemming]

Osteoporosis is caused by the failure to differentiate osteoblasts. I am not sure whether Osteopenia is essentially the same or not. That links to the energy levels of the cells which is an aging thing. As Rapamyin fixes that issue it is probably Rapamycin rather than naltrexone. I am not aware of what effects naltrexone would have in this situation.

[WJ_PhD]

Not to hate but I already posted this here in case someone wants to read the other comments

Case study report of PEARL female trial participant with osteopenia showing unexpected beneficial increase in bone mineral density (BMD)

Cureus 2025 Jan 14;17(1):e77435. doi: [10.7759/cureus.77435] (Unexpected Increase in Bone Mineral Density With Rapamycin and Low-Dose Naltrexone: A Case Report of a 52-Year-Old Woman With Osteopenia | Cureus) Unexpected Increase in Bone Mineral Density With Rapamycin and Low-Dose Naltrexone: A Case Report of a 52-Year-Old Woman With Osteopenia Editors: Alexander Muacevic, John R Adler PMCID: PMC11825221 PMID: 39958011 Abstract Osteopenia and osteoporosis are prevalent bone disorders characterized by reduced bone mineral density (BMD), leading to an increased risk of fractures. This case report presents a 52-year-old Caucasian female patient with osteopenia who experienced an unexpected 15.9% increase in lumbar spine BMD within two years after enrolling in a clinical trial involving low-dose rapamycin and subsequently starting low-dose naltrexone. This case potentially opens novel treatment strategies for bone density improvement in aging populations.

[channel_locks]

oops sorry. I don’t see how to delete.